^
Association details:
Evidence:
Evidence Level:
Sensitive: C1 - Off-label
  (Approved for Non Small Cell Lung Cancer)
New
Excerpt:
On February 16, 2024, the Food and Drug Administration approved osimertinib (Tagrisso, AstraZeneca Pharmaceuticals LP) with platinum-based chemotherapy for patients with locally advanced or metastatic non-small cell lung cancer (la/mNSCLC) whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR Mutations

Excerpt:
...- Patients must have adequate archival material from a previous biopsy to determine EGFR mutation status and Cripto-1 expression, or undergo a biopsy of fresh tissue of the primary cancer or a metastatic site in order to make these determinations, if archival material is...
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

OCEANiC: A Phase II, Open-label, Multi-centre Clinical Trial of Osimertinib With or Without Adjuvant Chemotherapy Guided by Tumour NGS Co-mutation Status and ctDNA Detection in Patients WithnStage IIA-IIIA EGFR-Mutant Non Small Cell Lung Cancer Following Complete Surgical Resection

Excerpt:
...Documented evidence of EGFR mutation (at any time since the initial diagnosis of NSCLC) known to be sensitive to osimertinib. ...
Less C2 evidence
Evidence Level:
Sensitive: C4 – Case Studies
Title:

EGFR-Mutated Lung Adenocarcinoma Successfully Treated With Osimertinib After Spontaneous Transformation to SCLC and Adenocarcinoma With Neuroendocrine Differentiation: Case Report

Published date:
12/03/2021
Excerpt:
Here, we report a case of spontaneously transformed EGFR-mutant SCLC and neuroendocrine-differentiated LUAD successfully treated with osimertinib…SCLC cells were again positive for EGFR (Fig. 1F)…EGFR genotyping using a pleural fluid cell block identified an identical Del19. Treatment with osimertinib (80 mg/d) was initiated...osimertinib treatment was continued beyond progressive disease, with the pleural effusion remaining controlled for a total of 12 months from the initiation of the treatment (Fig. 2)....Combined assessment of EGFR mutation status and EGFR pathway activity would predict the efficacy of EGFR TKIs in patients with EGFR-mutated spontaneously transformed SCLC.
DOI:
https://doi.org/10.1016/j.jtocrr.2021.100264